The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Abstract
FK506 and rapamycin are related immunosuppressive compounds that block helper T cell activation by interfering with signal transduction. In vitro, both drugs bind and inhibit the FK506-binding protein (FKBP) proline rotamase. Saccharomyces cerevisiae cells treated with rapamycin irreversibly arrested in the G1 phase of the cell cycle. An FKBP-rapamycin complex is concluded to be the toxic agent because (i) strains that lack FKBP proline rotamase, encoded by FPR1 , were viable and fully resistant to rapamycin and (ii) FK506 antagonized rapamycin toxicity in vivo. Mutations that conferred rapamycin resistance altered conserved residues in FKBP that are critical for drug binding. Two genes other than FPR1 , named TOR1 and TOR2 , that participate in rapamycin toxicity were identified. Nonallelic noncomplementation between FPR1 , TOR1 , and TOR2 alleles suggests that the products of these genes may interact as subunits of a protein complex. Such a complex may mediate nuclear entry of signals required for progression through the cell cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffman, C. S., & Winston, F. (1987) · Gene · doi:10.1016/0378-1119(87)90131-4 · Cited by 2,479
Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A
Handschumacher, R. E., Harding, M. W., Rice, J., Drugge, R. J., & Speicher, D. W. (1984) · Science · doi:10.1126/science.6238408 · Cited by 1,673
Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
Fischer, G., Wittmann-Liebold, B., Lang, K., Kiefhaber, T., & Schmid, F. X. (1989) · Nature · doi:10.1038/337476a0 · Cited by 1,407
A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase
Harding, M. W., Galat, A., Uehling, D. E., & Schreiber, S. L. (1989) · Nature · doi:10.1038/341758a0 · Cited by 1,396
Laboratory course manual for methods in yeast genetics
Sherman, F., Fink, G. R., & Hicks, J. B. (1986) · Cold Spring Harbor Laboratory eBooks · Cited by 1,231
Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin
Takahashi, N., Hayano, T., & Suzuki, M. (1989) · Nature · doi:10.1038/337473a0 · Cited by 1,078
Contingent Genetic Regulatory Events in T Lymphocyte Activation
Crabtree, G. R. (1989) · Science · doi:10.1126/science.2783497 · Cited by 1,072
Siekierka, J. J., Hung, S. H. Y., Poe, M., Lin, C. S., & Sigal, N. H. (1989) · Nature · doi:10.1038/341755a0 · Cited by 1,010
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 696
Cited by
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationCalcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“An elegant chemogenomic strategy in budding yeast identified the target of rapamycin (TOR) and established its role in nutrient sensing (Heitman et al., 1991) before the mammalian target of rapamycin (mTOR; also known as the mechanistic target of rapamycin) was discovered and was shown to integrate…”
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Self-citationLoewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Self-citationOsmotic Stress Signaling and Osmoadaptation in Yeasts
Hohmann, S. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.300-372.2002 · Cited by 1,767
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks
Alers, S., Löffler, A. S., Wesselborg, S., & Stork, B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06159-11 · Cited by 1,483
“TOR was initially identified as a target for the antifungal properties of rapamycin, which leads to growth inhibition in Saccharomyces cerevisiae (35).”
BackgroundFrom discoveries in ageing research to therapeutics for healthy ageing
Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019) · Nature · doi:10.1038/s41586-019-1365-2 · Cited by 1,389
Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast
Noda, T., & Ohsumi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3963 · Cited by 1,309
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229
Chung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,150
Cell Wall Integrity Signaling in Saccharomyces cerevisiae
Levin, D. E. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.2.262-291.2005 · Cited by 1,136
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,095
mTOR as a central hub of nutrient signalling and cell growth
Kim, J., & Guan, K.-L. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,072
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Self-citationDysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
ROS, mitochondria and the regulation of autophagy
Scherz-Shouval, R., & Elazar, Z. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.009 · Cited by 954
The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors
Beck, T., & Hall, M. N. (1999) · Nature · doi:10.1038/45287 · Cited by 924
Self-citationTarget of Rapamycin (TOR) in Nutrient Signaling and Growth Control
Loewith, R., & Hall, M. N. (2011) · Genetics · doi:10.1534/genetics.111.133363 · Cited by 910
Self-citationIsolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
The DNA-dependent protein kinase
Smith, G. C. M., & Jackson, S. P. (1999) · Genes & Development · doi:10.1101/gad.13.8.916 · Cited by 887
Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., & Blenis, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.200-216.2004 · Cited by 868
Immunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 834
Self-citationThe mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control
González, A., Hall, M. N., Lin, S.-C., & Hardie, D. G. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.015 · Cited by 797
Self-citationTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
Regulation of starvation- and virus-induced autophagy by the eIF2α kinase signaling pathway
Tallóczy, Z., Jiang, W., Virgin, H. W., Leib, D. A., Scheuner, D., Kaufman, R. J., Eskelinen, E.-L., & Levine, B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012485299 · Cited by 741
Nutrient sensing and TOR signaling in yeast and mammals
González, A., & Hall, M. N. (2017) · The EMBO Journal · doi:10.15252/embj.201696010 · Cited by 732
Self-citationBrunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., & Abraham, R. T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00911.x · Cited by 723
TOR controls translation initiation and early G1 progression in yeast.
Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., & Hall, M. N. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.25 · Cited by 715
Self-citationRapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.
Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., & Sonenberg, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00398.x · Cited by 677
Self-citationThe mRNA 5′ cap-binding protein eIF4E and control of cell growth
Sonenberg, N., & Gingras, A.-C. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673
Heat shock proteins: molecular chaperones of protein biogenesis
Craig, E. A., Gambill, B. D., & Nelson, R. J. (1993) · Microbiological Reviews · doi:10.1128/mmbr.57.2.402-414.1993 · Cited by 670
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
With TOR, Less Is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging
Kapahi, P., Chen, D., Rogers, A. N., Katewa, S. D., Li, P. W.-L., Thomas, E. L., & Kockel, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.05.001 · Cited by 660
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640
Self-citationProlyl cis-trans isomerization as a molecular timer
Lu, K. P., Finn, G., Lee, T. H., & Nicholson, L. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.35 · Cited by 652
Regulation of cellular growth by the Drosophila target of rapamycin dTOR
Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C., & Neufeld, T. P. (2000) · Genes & Development · doi:10.1101/gad.835000 · Cited by 624
mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
Jia, K., Chen, D., & Riddle, D. L. (2004) · Development · doi:10.1242/dev.01255 · Cited by 615
The target of rapamycin (TOR) proteins
Raught, B., Gingras, A.-C., & Sonenberg, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121145898 · Cited by 605
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., & Crabtree, G. R. (1992) · Nature · doi:10.1038/358070a0 · Cited by 595
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J.-P., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 589
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
The TOR signaling cascade regulates gene expression in response to nutrients
Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Di Como, C. J., & Heitman, J. (1999) · Genes & Development · doi:10.1101/gad.13.24.3271 · Cited by 582
Self-citationmTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
The Anchor-Away Technique: Rapid, Conditional Establishment of Yeast Mutant Phenotypes
Haruki, H., Nishikawa, J., & Laemmli, U. K. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.020 · Cited by 566
TOR signalling in bugs, brain and brawn
Jacinto, E., & Hall, M. N. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1018 · Cited by 565
Self-citationmTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 562
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
Autophagy in the Eukaryotic Cell
Reggiori, F., & Klionsky, D. J. (2002) · Eukaryotic Cell · doi:10.1128/ec.01.1.11-21.2002 · Cited by 548
The modular phosphorylation and activation of p70s6k
Pullen, N., & Thomas, G. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00323-2 · Cited by 540
Yang, Q., & Guan, K.-L. (2007) · Cell Research · doi:10.1038/cr.2007.64 · Cited by 535
mTORC1 Controls Phase Separation and the Biophysical Properties of the Cytoplasm by Tuning Crowding
Delarue, M., Brittingham, G. P., Pfeffer, S., Surovtsev, I. V., Pinglay, S., Kennedy, K. J., Schaffer, M., Gutierrez, J. I., Sang, D., Poterewicz, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.042 · Cited by 535
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
“Two additional proteins required for its effects in yeast were identified in a genetic screen in 1991 and termed target of rapamycin 1 (TOR1) and TOR2 (5).”
BackgroundWhere is mTOR and what is it doing there?
Betz, C., & Hall, M. N. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201306041 · Cited by 527
Self-citationHardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14866 · Cited by 522
Calcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Self-citationExploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast
Parsons, A. B., Lopez, A., Givoni, I. E., Williams, D. E., Gray, C. A., Porter, J., Chua, G., Sopko, R., Brost, R. L., Ho, C.-H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.040 · Cited by 515
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Rapamycin inhibits vascular smooth muscle cell migration.
Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., & Marks, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119038 · Cited by 511
XPB, a subunit of TFIIH, is a target of the natural product triptolide
Titov, D. V., Gilman, B., He, Q.-L., Bhat, S., Low, W.-K., Dang, Y., Smeaton, M., Demain, A. L., Miller, P. S., Kugel, J. F., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.522 · Cited by 509
Twenty-five years of mTOR: Uncovering the link from nutrients to growth
Sabatini, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716173114 · Cited by 501
Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases.
Di Como, C. J., & Arndt, K. T. (1996) · Genes & Development · doi:10.1101/gad.10.15.1904 · Cited by 494
The expanding TOR signaling network
Martin, D. E., & Hall, M. N. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.008 · Cited by 494
Self-citationExpression and disruption of the Arabidopsis TOR (target of rapamycin) gene
Menand, B., Desnos, T., Nussaume, L., Berger, F., Bouchez, D., Meyer, C., & Robaglia, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092141899 · Cited by 493
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
“Yeast TOR was initially identified as the inhibitory target of the bacterial macrolide rapamycin, produced by the soil bacterium Streptomyces hygroscopicus ( 15 ).”
BackgroundmTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
Search and Discovery Strategies for Biotechnology: the Paradigm Shift
Bull, A. T., Ward, A. C., & Goodfellow, M. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.3.573-606.2000 · Cited by 477
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease
Sciarretta, S., Volpe, M., & Sadoshima, J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302022 · Cited by 453
Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441
Metadata
- Authors
- Heitman, J., Movva, N. R., & Hall, M. N.
- Venue
- Science
- Published
- 1991-08-23
- Volume
- 253
- Issue
- 5022
- Pages
- 905-909
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2063013559
- Cited by
- 2,006
- References
- 41
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.